What key updates or milestones is Akari Therapeutics likely to announce during the webinar?

Likely content of the webinar

Given the timing (mid‑August) and the typical agenda of a Webull “Corporate Connect” session, Akari Therapeutics (AKRI) will almost certainly use the platform to deliver four‑to‑five headline‑type updates that are material to shareholders and the broader biotech market:

1. Clinical‑program milestone updates – most likely an interim data read‑out or a timeline confirmation for the company’s lead candidates (e.g., AK-001/AK-02) in the late‑stage trial pipeline (e.g., oncology, immunology, or neuro‑degeneration). The company may also disclose regulatory interactions (FDA/EMA meeting outcomes, IND filing status, or a planned BLA submission date).
   
2. Commercial‑or‑partnering news – a new strategic partnership, licensing deal, or out‑license of a platform technology. This would often be paired with a cash‑flow projection (e.g., milestone payments or royalty streams) that can materially lift the balance sheet.
   
3. Financial guidance and capital‑raising – an update on the Q2‑Q3 cash burn rate, runway extension, and possibly a follow‑on equity offering or convertible debt to fund the upcoming trial phases. The company may also give a revised 2025‑2026 revenue outlook tied to the anticipated product launch.
   
4. Corporate governance or ESG items – a new board appointment, a change in the executive team, or a grant/award from a reputable institution that validates the science.
   

Trading implications

Technically, AKRI has been trading in a tight range with modest volume (sentiment score 20 suggests modest interest). If the webinar delivers positive trial data, a definitive regulatory timeline, or a sizable partnership, we can expect a breakout above the recent resistance around $5.30–$5.50 with volume spikes on the breakout day, potentially triggering a short‑squeeze on any existing short positions. Conversely, a delay‑type announcement (e.g., postponed trial) or a weak cash‑position update would likely trigger a sell‑off toward support at $4.70‑$4.90, and the stock could retest the 200‑day MA (~$5.00).

Actionable take‑away: Enter a position on the back‑of‑the‑envelope that the webinar will be a catalyst. If you are bullish, consider a buy‑the‑dip if AKRI dips below $4.80 before the call (risk‑managed with a stop at $4.40). If you are risk‑averse, hold off on new long positions until the webcast is over; then look for a break above $5.40 on high volume as a trigger to go long, or short if the call yields a negative update and the stock drops below the 50‑day EMA (~$4.95). Keep an eye on the pre‑market and post‑webinar price action; a strong positive reaction will likely hold the next resistance and open a short‑term uptrend, while a weak update will test the lower trendline and may prompt a re‑evaluation of the short‑term downside.